MedPath

Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors

Phase 2
Conditions
Brain and Central Nervous System Tumors
Neuroblastoma
Registration Number
NCT00281905
Lead Sponsor
Children's Cancer and Leukaemia Group
Brief Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy after chemotherapy may kill any remaining tumor cells.

PURPOSE: This phase II trial is studying how well giving combination chemotherapy together with or without radiation therapy works in treating children with brain tumors.

Detailed Description

OBJECTIVES:

* Determine the response rate in children under 36 months of age with primary brain or brain stem tumors treated with vincristine, methotrexate, carboplatin, cyclophosphamide, and cisplatin with or without radiotherapy.

* Determine the event-free survival and overall survival in children treated with this regimen.

* Determine the pattern of local recurrence or occurrence of CNS metastases in children treated with this regimen.

* Determine the quality of life in children treated with this regimen.

* Determine the tolerability and long-term toxicity of this regimen in these children.

* Determine the proportion of children who require radiotherapy after treatment with this regimen.

* Determine the prognosis of children who receive both chemotherapy and radiotherapy.

* Determine the nature and behavior of brain tumors in very young children.

OUTLINE: This is a multicenter study.

* Chemotherapy: Patients receive vincristine IV on days 0, 14, and 28; carboplatin IV over 4 hours on day 0; methotrexate IV continuously over 24 hours on day 14; cyclophosphamide IV over 4 hours on day 28; and cisplatin IV continuously over 48 hours on days 42 and 43. Courses repeat every 56 days (8 weeks) for up to 12 months. Patients who achieve a complete response proceed to observation, as do those achieving a partial response with no tumor present on biopsy. Patients with biopsy proven residual tumors after 12 months of chemotherapy or recurrent tumors that don't have the potential to spread through the cerebrospinal fluid (CSF) proceed to local radiotherapy. Patients with unresponsive disease or progressive disease that has the potential to spread through the CSF proceed to craniospinal radiotherapy.

* Local radiotherapy: Patients undergo local radiotherapy 5 days a week for 5-5ยฝ weeks.

* Craniospinal radiotherapy: Patients undergo craniospinal radiotherapy 5 days a week for 4 weeks.

Quality of life is assessed periodically.

After completion of study treatment, patients are followed periodically for at least 2 years.

PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Response rate
Local recurrence or occurrence of CNS metastases
Event-free survival
Quality of survival
Long-term toxicity
Tolerance
Proportion of patients requiring radiotherapy
Prognosis of children who receive both chemotherapy and radiotherapy
Nature and behavior of brain tumors
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (20)

Our Lady's Hospital for Sick Children

๐Ÿ‡ฎ๐Ÿ‡ช

Dublin, Ireland

Birmingham Children's Hospital

๐Ÿ‡ฌ๐Ÿ‡ง

Birmingham, England, United Kingdom

Royal Liverpool Children's Hospital, Alder Hey

๐Ÿ‡ฌ๐Ÿ‡ง

Liverpool, England, United Kingdom

Institute of Child Health at University of Bristol

๐Ÿ‡ฌ๐Ÿ‡ง

Bristol, England, United Kingdom

Sir James Spence Institute of Child Health

๐Ÿ‡ฌ๐Ÿ‡ง

Newcastle-Upon-Tyne, England, United Kingdom

Queen's Medical Centre

๐Ÿ‡ฌ๐Ÿ‡ง

Nottingham, England, United Kingdom

Central Manchester and Manchester Children's University Hospitals NHS Trust

๐Ÿ‡ฌ๐Ÿ‡ง

Manchester, England, United Kingdom

Leicester Royal Infirmary

๐Ÿ‡ฌ๐Ÿ‡ง

Leicester, England, United Kingdom

Royal London Hospital

๐Ÿ‡ฌ๐Ÿ‡ง

London, England, United Kingdom

Children's Hospital - Sheffield

๐Ÿ‡ฌ๐Ÿ‡ง

Sheffield, England, United Kingdom

Southampton General Hospital

๐Ÿ‡ฌ๐Ÿ‡ง

Southampton, England, United Kingdom

Leeds Cancer Centre at St. James's University Hospital

๐Ÿ‡ฌ๐Ÿ‡ง

Leeds, England, United Kingdom

Oxford Radcliffe Hospital

๐Ÿ‡ฌ๐Ÿ‡ง

Oxford, England, United Kingdom

Royal Hospital for Sick Children

๐Ÿ‡ฌ๐Ÿ‡ง

Glasgow, Scotland, United Kingdom

Great Ormond Street Hospital for Children NHS Trust

๐Ÿ‡ฌ๐Ÿ‡ง

London, England, United Kingdom

Royal Aberdeen Children's Hospital

๐Ÿ‡ฌ๐Ÿ‡ง

Aberdeen, Scotland, United Kingdom

Childrens Hospital for Wales

๐Ÿ‡ฌ๐Ÿ‡ง

Cardiff, Wales, United Kingdom

Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust

๐Ÿ‡ฌ๐Ÿ‡ง

Cambridge, England, United Kingdom

Royal Marsden NHS Foundation Trust - Surrey

๐Ÿ‡ฌ๐Ÿ‡ง

Sutton, England, United Kingdom

Royal Belfast Hospital for Sick Children

๐Ÿ‡ฌ๐Ÿ‡ง

Belfast, Northern Ireland, United Kingdom

ยฉ Copyright 2025. All Rights Reserved by MedPath